FacebookTwitterGoogle PlusLinkedin

Menu

Ongoing Clinical Trials studies

We encourage patients to learn more about what clinical trials are currently offered in our center.

Studies Actively Recruiting Participants

  1. Study sponsored by Akebia. It evaluates the effect of Oral Hypoxemia Inducing Factor in patients with anemia of chronic kidney disease. This medication will be a pill, and meant to stimulate low blood oxygen levels, which will stimulate the kidneys to generate a hormone to make more red blood cells.

Inclusion criteria: Patients with a chronic Kidney Disease and are not yet on dialysis with a HGB between 9.5 g/dl and 12.0 g/dl, may or may not be requiring epogen, and have had no recent gastro-intestinal bleeding or history of thrombus (i.e. blood clot) or history of lupus or organ transplant.

To participate must be an active outpatient at Renal Medicine Associates.

  1. Study to evaluate new medications for Anemia with an orally administered medication in patients with End stage renal disease and Patients (who are on dialysis) with low hemoglobin levels (red blood cell count), sponsored by Fibrinogen Therapeutics pharmaceuticals.

Goal: To evaluate the hemoglobin the response of an orally administered a new medication for anemia management. This medication will be a pill, and meant to stimulate low blood oxygen levels which will stimulate the kidneys to generate a hormone to make more red blood cells.

Inclusion criteria: Patients with  End stage Renal disease (on dialysis) with a hemoglobin between 9.0 g/dl and 12.0 g/dl, may or may not requiring epogen, and have had no recent gastro-intestinal bleeding or history of thrombus (i.e. blood clot) or history of lupus.

To participate must be on active dialysis at one of Fresenius medical services. Study is actively recruiting at local FMC dialysis center.

  1. Study sponsored by Pfizer. It evaluates the effect of a CCR4/5 inhibitor on reduction of proteinuria in patients with diabetic nephropathy.

Inclusion criteria: Patients with Chronic Kidney diseases resulting from type 2 diabetes have protein in the urine and have been actively treated for hypertension and have had no history of peripheral vascular disease or obstructive uropathy or history of lupus or organ transplant.

To participate must be an active outpatient at Renal Medicine Associates.

  1. Study sponsored by Abbvie. It evaluates the effect of an Endothelin receptor inhibitor on proteinuria reduction in patients with diabetic nephropathy.

Inclusion criteria: Patients with Chronic Kidney diseases resulting from type 2 diabetes have protein in the urine and are actively being treated for hypertension and diabetes. Patients must not have moderate or severe swelling. Patients with a history of heart failure and patients receiving dialysis or those that are being evaluated for kidney transplant may not qualify for the study.

To participate must be an active outpatient at Renal Medicine Associates.

  1. Access study to evaluate effect of Canagloflozin on patients who have Type II diabetes, diabetic nephropathy (protein leaking from the kidneys) and High blood Pressure. The goal is to evaluate if this medication reduces the risk of heart failure, cardiovascular death, myocardial infarction, stroke congestive heart failure and improves kidney function. Medication sponsored by Jensen & Jensen.

Inclusion Criteria: Patients with Chronic Kidney diseases resulting from Type II Diabetes have protein in the urine and have been actively treated for Hypertension. To participate must be an active outpatient at Renal Medicine Associates.